Glucocorticoid-induced osteoporosis: when and who should we treat?

被引：2
|
作者：
Morel, Gauthier [1 ]
Biver, Emmanuel [2 ]
Borg, Severine [3 ]
Chopin, Florence [4 ]
Hoppe, Emmanuel [5 ]
Rajzbaum, Gerald [6 ]
机构：
[1] Ctr Hosp, Serv Rhumatol, F-59322 Valenciennes, France
[2] Hop Roger Salengro, Dept Univ Rhumatol, F-59037 Lille, France
[3] Hop Purpan, Serv Rhumatol, F-31059 Toulouse, France
[4] CHU Bellevue, INSERM, U1059, Serv Rhumatol, F-42055 St Etienne, France
[5] Univ Angers, Serv Rhumatol, CHU Angers, F-49033 Angers 01, France
[6] Grp Hosp Paris St Joseph, Serv Rhumatol, F-75674 Paris 14, France
来源：
JOINT BONE SPINE | 2011年 / 78卷
关键词：
Osteoporosis; Bone mineral density; Fracture; Glucocorticoids; Treatment; CORTICOSTEROID-INDUCED OSTEOPOROSIS; ORAL CORTICOSTEROIDS; RHEUMATOID-ARTHRITIS; VERTEBRAL FRACTURE; RISK; PREVENTION; EPIDEMIOLOGY; METAANALYSIS; MANAGEMENT; THRESHOLD;
D O I：
10.1016/S1297-319X(11)70008-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：S214 / S217
页数：4
相关论文
共 50 条
  • [31] Glucocorticoid-induced osteoporosis
    Tamura, Y
    Okinaga, H
    Takami, H
    BIOMEDICINE & PHARMACOTHERAPY, 2004, 58 (09) : 500 - 504
  • [32] GLUCOCORTICOID-INDUCED OSTEOPOROSIS
    Lorena Brance, Maria
    Brun, Lucas R.
    REVISTA MEDICA DE ROSARIO, 2008, 74 (02): : 78 - 88
  • [33] Baseline Glucocorticoid Dose and Bone Mineral Density Response with Teriparatide or Alendronate Therapy in Patients with Glucocorticoid-induced Osteoporosis
    Devogelaer, Jean-Pierre
    Adler, Robert A.
    Recknor, Chris
    See, Kyoungah
    Warner, Margaret R.
    Wong, Mayme
    Krohn, Kelly
    JOURNAL OF RHEUMATOLOGY, 2010, 37 (01) : 141 - 148
  • [34] Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?
    Eileen Rife
    Jennifer Elise Abdalla
    Jose Leon de la Rocha
    Nkechinyere Emejuaiwe
    SN Comprehensive Clinical Medicine, 5 (1)
  • [35] Bisphosphonates and glucocorticoid-induced osteoporosis: cons
    Willem F. Lems
    Kenneth Saag
    Endocrine, 2015, 49 : 628 - 634
  • [36] Denosumab in the treatment of glucocorticoid-induced osteoporosis
    Benlidayi, Ilke Coskun
    RHEUMATOLOGY INTERNATIONAL, 2018, 38 (11) : 1975 - 1984
  • [37] High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first
    Lespessailles, E.
    Chapurlat, R.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (10) : 1829 - 1834
  • [38] Ukrainian guideline for the prevention and treatment of glucocorticoid-induced osteoporosis
    Grygorieva, N. V.
    Kovalenko, V. M.
    Korzh, M. O.
    Tronko, M. D.
    Golovach, I. Yu.
    Dedukh, N. V.
    Rekalov, D. G.
    Strafun, S. S.
    Smiyan, S. I.
    Golubovska, O. A.
    Dziublyk, Ya. O.
    Kharchenko, N. V.
    Protsenko, G. O.
    Garmish, O. O.
    Orlenko, V. L.
    Klymovytskyy, F. V.
    Musiienko, A. S.
    Karasevska, T. A.
    Ukrainian Assoc Osteoporosis
    ARCHIVES OF OSTEOPOROSIS, 2025, 20 (01)
  • [39] Management of glucocorticoid-induced osteoporosis
    Compston, Juliet
    NATURE REVIEWS RHEUMATOLOGY, 2010, 6 (02) : 82 - 88
  • [40] Densitometry in glucocorticoid-induced osteoporosis
    Maricic, M
    Gluck, O
    JOURNAL OF CLINICAL DENSITOMETRY, 2004, 7 (04) : 359 - 363
12345